


grade 3 should promptly be referred for early LT. The redefinition of ACLF in AH is essential for better quantifying the severity and determining therapeutic goals.

Cumulative survival in patients with alcohol-associated hepatitis according to Acute-on-chronic (ACLF) grade



No at risk					
No ACLF	186	126	107	94	80
Grade 1	59	31	26	21	18
Grade 2	110	71	62	57	46
Grade 3	223	63	35	28	24

Figure

<https://doi.org/10.1016/j.aohep.2024.101603>

OP-6 EVALUATION OF THE HEPATOPROTECTIVE ACTIVITY OF *Flourensia cernua* AND ITS IMPACT ON THE AEROBIC INTESTINAL MICROBIOTA IN A VALPROIC ACID-INDUCED DAMAGE MODEL IN WISTAR RATS

Liliana Torres González¹,
José Miguel De la Rosa García¹,
Jorge Martín Llaca Díaz², Lorena Salazar Cavazos²,
Humberto Rodríguez Rocha³, Aracely García García³,
Catalina Leos Rivas⁴,
Veronica Mayela Rivas Galindo⁵,
Luis Alejandro Pérez López⁵,
Diana Patricia Moreno Peña¹,
Diana Raquel Rodríguez Rodríguez¹,
Linda E. Muñoz Espinosa¹, Paula Cordero Pérez¹

¹ Liver Unit, Department of Internal Medicine, University Hospital "Dr. José E. González", Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico

² Department of Clinical Pathology, University Hospital "Dr. José E. González", Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico

³ Department of Histology, Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico

⁴ Department of Chemistry, Faculty of Biological Sciences, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico

⁵ Department of Analytical Chemistry, Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico

Conflict of interest: No

Introduction and Objectives: Liver disease is a health problem that accounts for more than 2 million deaths per year worldwide. Valproic acid (VPA) has been used as a hepatotoxic agent in animal

models to reproduce liver damage and test future therapeutic strategies. *Flourensia cernua* (Fc) is a plant that contains compounds with antioxidant activity, which may have a potential hepatoprotective effect.

The aim was to evaluate the hepatoprotective activity of *Flourensia cernua* and its impact on aerobic intestinal microbiota in a valproic acid-induced damage model in Wistar rats.

Patients / Materials and Methods: Seven groups were used (n=6): 1) Sham, 2) VPA, 500 mg/kg of VPA/d/7d i.p., 3) Fc extract at 200 mg/kg/d/3d p.o., 4) Fc extract at 400 mg/kg/d/3d p.o., 5) VPA + Fc 200 mg/kg/d/3d p.o., 6) VPA + Fc 400 mg/kg/d/3d p.o., 7) VPA + Silibinin 200 mg/kg/d/3d p.o.; subsequently, the animals were sacrificed, and samples of faeces, blood, and liver tissue were taken for aerobic intestinal microbiota (AIM), biochemical markers, oxidative stress, and histological analysis, respectively. Data was analyzed using Prism software (v. 10.0.0; GraphPad). $P < 0.05$ was statistically significant.

Results and Discussion: VPA significantly increased ALT, AST and decreased total proteins vs. Sham. There was no alteration of transaminases at both tested doses of Fc extract. Only the VPA + Fc 400 mg/kg group showed a significant reduction in ALT, AST, SOD, and MDA vs. VPA, similar to silibinin. The histological analysis did not show significant changes in the study groups. MALDI-TOF primarily identified *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Escherichia coli*, and *Ochrobactrum intermedium* as AIM in the different study groups.

Conclusions: The hydroalcoholic extract of *F. cernua* did not show toxicity at the evaluated doses, showed a hepatoprotective effect at 400 mg/kg, and did not modify AIM. VPA decreased AIM, and *F. cernua* showed a trend to partially restore the normal bacterial count, similar to silibinin.

<https://doi.org/10.1016/j.aohep.2024.101604>

OP-7 Further exploration of differences between lean and non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) in Latino subjects: PNPLA3 frequency and lipidomic profiles

MARIA AYALA VALVERDE¹, Jorge Arnold Alvarez¹,
Gustavo Ayares², Francisco Barrera¹, Daniel Cabrera¹,
Luis Antonio Diaz¹, Juan Pablo Arab³,
Ibon Martinez-Arranz⁴, Cristina Alonso⁴,
Jesús M. Bañales⁵, Marco Arrese¹

¹ Departamento de Gastroenterología Facultad de Medicina Pontificia Universidad Católica de Chile, Chile

² Pontificia Universidad Católica de Chile, Santiago, Chile

³ Virginia Commonwealth University School of Medicine, Richmond, VA (USA), Chile

⁴ OWL Metabolomics, Derio (Spain), Chile

⁵ Biogipuzcoa Research Institute, San Sebastian (Spain), Chile

Conflict of interest: Yes, Fondecyt # 1241450

Introduction and Objectives: Background: There is limited information on features of lean MASLD patients in Latino subjects. We aimed to analyze the features of MASLD in Chilean patients with normal body mass index (BMI), the frequency of the rs738409 risk polymorphism (PNPLA3 I148M variant) and metabolomic profiles in Chilean individuals with MASLD.

Patients / Materials and Methods: A cross-sectional study involving 181 randomly-selected participants diagnosed with MASLD from the prospective Maule Cohort (BMC Public Health. 2016;16:122). Participants were categorized into lean, overweight, and obese groups